Showing 94 of 94on this page. Filters & sort apply to loaded results; URL updates for sharing.94 of 94 on this page
Effect of AZD5305 on PARP2 retention on DNA. (A) The crystal structure ...
AZD5305 | PARP | TargetMol
AZD5305 inhibits and traps selectively PARP1 in cells. A, Left ...
RCSB PDB - 9ETQ: Crystal structure of PARP1 catalytic domain bound to ...
Medchemexpress LLC HY-132167 5mg , AZD5305 CAS:2589531-76-8 Purity:>98% ...
AstraZeneca's second-generation PARP inhibitor AZD5305 is applied for ...
新一代 PARP 抑制剂！阿斯利康 AZD5305 国内启动临床_Insight_奥拉帕利_数据库
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression ...
AZD5305 / AstraZeneca
Azd5305 – Application in Therapy and Current Clinical Research
AZD5305 selectively targets cancer cells with HRR-deficiency, inducing ...
AZD5305 has reduced hematological toxicity in monotherapy and ...
Abstract 296: Structure-based and property-based drug design of AZD5305 ...
Study of AZD5305 Alone and with Other Cancer Drugs for Patients with ...
AZD5305 for Prostate Cancer Clinical Trial 2024 | Power
AZD5305 + Darolutamide for Prostate Cancer Clinical Trial 2024 | Power
AZD5305 | 2589531-76-8 | AbMole | Saruparib; AZD-5305
Matrix effect, recovery, and process efficiency of AZD5305 (mean ± SD ...
Cancer Discovery on Twitter: "#NewsInBrief: AZD5305 More Tolerable than ...
Saruparib (AZD5305) | PARP Inhibitor | MedChemExpress
Saruparib (AZD5305) | PARP inhibitor | Mechanism | Concentration
AZD-5305 | 2589531-76-8
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条__新浪财经
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl ...
How does AstraZeneca's PARP inhibitor differentiate?
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
PARP抑制剂：氟唑帕利、帕米帕利、AZD5305对比-觅健
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA ...
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and ...
saruparib (AZD5305) / AstraZeneca
从构象稳定性与水分子替换角度理解PARP1抑制剂HRS1167的设计
PARP2 Chemiluminescent Assay Kit PARP2 80552
Preclinical Characterization of AZD5305, A Next-Generation, Highly ...
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
Design, Synthesis, and Biological Evaluation of Potent and Selective ...
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody ...
(PDF) Current status and future promise of next-generation poly (ADP ...
AACR 2022: PETRA: First in class, first in human trial of the next ...
AZD5305的晶型及其制备方法和用途与流程
Saruparib, A first-in-class PARP1 Selective Inhibitor, Can Be Used for ...
Reduced Ventricular Proarrhythmic Potential of the Novel Combined Ion ...
PARP赛道新势力：氟唑帕利、帕米帕利、AZD5305_治疗
Computational Study on New Natural Compound Inhibitors of Pyruvate ...
盛湲教授：ADC药物的狂欢—AACR T-DXd最新数据盘点_研究_细胞_治疗
A unified mechanism for PARP inhibitor-induced PARP1 chromatin ...
阿斯利康申报下一代 PARP 抑制剂，接棒“重磅炸弹”奥拉帕利 7 月 6 日，CDE 官网显示， 阿斯利康 在国内申报了继奥拉帕利之后的第二 ...
AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo ...
80551 | PARP1 Chemiluminescent Assay Kit Clinisciences
ASCO 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo ...
CDSCO panel approves AstraZeneca's Protocol Amendment proposal for ...
PARP2 Olaparib Competitive Inhibitor Assay Kit PARP2 82294
